Drug intelligence / Profile preview

MH-712

Development stage: Preclinical
Lead developer: Meter Health

Overview

MH-712 is an investigational drug candidate being developed by Meter Health for the treatment of oncology-incident clinically significant hiccups. Hiccups in cancer patients are often persistent or intractable, frequently triggered by chemotherapy (especially cisplatin and dexamethasone) or the underlying malignancy itself, significantly impacting quality of life. As of early 2024, MH-712 is in the IND-enabling phase of development. While the specific mechanism of action and modality have not been publicly disclosed by Meter Health, the asset is part of their pipeline targeting supportive care in oncology.

Beyond the preview

Go deeper on MH-712.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MH-712.

Explore the full profile